



# MARKET RELEASE

23 January 2018

**MGC PHARMACEUTICALS LTD**

**TRADING HALT**

The securities of MGC Pharmaceuticals Ltd (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Thursday, 25 January 2018 or when the announcement is released to the market.

Security Code:                   MXC

Jeremy Newman  
**Senior Adviser, Listings Compliance (Perth)**

23 January 2018

Australian Securities Exchange  
Level 40, Central Park  
152-158 St Georges Tce  
Perth WA 6000

Via email: [tradinghaltspert@asx.com.au](mailto:tradinghaltspert@asx.com.au)

Dear Sir/Madam

The Directors of MGC Pharmaceuticals Ltd (the "Company") request that the Company's securities be placed in a voluntary trading halt immediately in accordance with ASX Listing Rule 17.1, pending the release of an announcement by the Company regarding the Good Manufacturing Practice (GMP) certification approval process being sought by the Company for its European Medicinal Cannabis Laboratory and Extraction Facility.

The Company requests that the trading halt end on the earlier of the commencement of normal trading on Thursday 25 January 2018, or when the announcement referred to above is released to the market.

The Company is not aware of any reason why the trading halt should not be granted, nor of any other information necessary to inform the market about the trading halt, and the Company confirms that the request for a trading halt is material.

Yours faithfully



Brett Mitchell  
Executive Chairman